Sovargen
sovargen.com
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Atinum Investment
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Atinum Investment Similar startupsby what they do, their industry and backers
Return Zero leads AI voice and language technology with top-tier STT and TTS technology and full-stack AI engineering capabilities.
Overview. MedInTech is driving a new wave of innovation in the endoscopy field through artificial intelligence and robotics technology.
Cloverleaf Bio | Developing a new class of RNA therapeutics to revolutionize cancer therapy.
Valo Health is a Boston biotechnology company founded in 2019 that applies computation across drug discovery. Its Opal platform links human…
Precision biomarkers that quantify functional brain change. Supporting drug development and brain health programs.
Ring Therapeutics is a biotechnology company creating novel vector conjugate medicines that carry more and reach further, expanding…
Overview
About us overview Leadership OVERVIEW A Global Leader in RNA Therapeutics for Intractable Genetic Brain Diseases Global Top-Tier R&D Capabilities Global Leader in Brain Somatic Mutation Research World-Class Expertise in Drug Development and Business Development Unique Platform Edge Low-frequency…
News
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that Sovargen Co., Ltd., a
Read more
Report
Kazia Therapeutics Limited: Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics
Read more
Report
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
--Kazia Therapeutics Limited, an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that Sovargen Co., Ltd., a biotechnology
Read more
Report
Kazia Therapeutics Gains $2 Million Milestone as Sovargen Doses First Paxalisib Patient in Rare Epilepsy Trial
Tipranks Press Release.
Read more
Report
Aimed Bio partners with Sovargen to co-develop AOCs and invest strategically
Aimed Bio partners with Sovargen to co-develop AOCs and invest strategically Partnership seeks to merge antibody targeting with oligo design for next-
Read more
Report
Pro access
Upgrade to see all 10 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.